About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company's lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: PCRX
- CUSIP: 69512710
- Previous Close: $43.70
- 50 Day Moving Average: $39.73
- 200 Day Moving Average: $37.15
- 52-Week Range: $29.95 - $65.64
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 46.49
- P/E Growth: 1.54
- Market Cap: $1.63B
- Outstanding Shares: 37,402,000
- Beta: 2.24
- Net Margins: -13.37%
- Return on Equity: -1.52%
- Return on Assets: -0.86%
Companies Related to Pacira Pharmaceuticals:
- Current Ratio: 1.60%
- Quick Ratio: 1.35%
What is Pacira Pharmaceuticals' stock symbol?
Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."
Where is Pacira Pharmaceuticals' stock going? Where will Pacira Pharmaceuticals' stock price be in 2017?
12 brokers have issued twelve-month price objectives for Pacira Pharmaceuticals' stock. Their forecasts range from $34.00 to $100.00. On average, they anticipate Pacira Pharmaceuticals' share price to reach $60.10 in the next year.
When will Pacira Pharmaceuticals announce their earnings?
Pacira Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
Who owns Pacira Pharmaceuticals stock?
Pacira Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (4.69%), State Street Corp (2.88%), Alyeska Investment Group L.P. (1.45%), Armistice Capital LLC (1.07%), Two Sigma Investments LP (0.64%) and Baillie Gifford & Co. (0.57%). Company insiders that own Pacira Pharmaceuticals stock include David M Stack, Gary W Pace, James B Jones, James S Scibetta, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings and Scott Braunstein.
Who sold Pacira Pharmaceuticals stock? Who is selling Pacira Pharmaceuticals stock?
Pacira Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Highland Capital Management LP, State Street Corp, Frontier Capital Management Co. LLC and Guggenheim Capital LLC. Company insiders that have sold Pacira Pharmaceuticals stock in the last year include David M Stack, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker and Mark A Kronenfeld.
Who bought Pacira Pharmaceuticals stock? Who is buying Pacira Pharmaceuticals stock?
Pacira Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Hodges Capital Management Inc., Armistice Capital LLC, Cortina Asset Management LLC, Alden Global Capital LLC, Two Sigma Investments LP, A.R.T. Advisors LLC and Bogle Investment Management L P DE. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include Gary W Pace, James B Jones, James S Scibetta, John P Phd Longenecker and Scott Braunstein.
How do I buy Pacira Pharmaceuticals stock?
Shares of Pacira Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Pacira Pharmaceuticals stock cost?
One share of Pacira Pharmaceuticals stock can currently be purchased for approximately $43.70.